Efficacy And Security In A 4-year Follow-up Of The Elevate-tn Research Comparing Acalabrutinib With Or With Out Obinutuzumab Versus Obinutuzumab Plus Chlorambucil In Treatment-naïve Chronic Lymphocytic Leukemia Pmc

Bruton tyrosine kinase inhibitors have improved persistent lymphocytic leukemia outcomes and supply a chemotherapy-free possibility . The BTK inhibitor ibrutinib, alone or with a CD20 antibody, demonstrated higher efficacy versus chemoimmunotherapy in treatment-naïve CLL [2–4]….

Read more